On Oct 29, major Wall Street analysts update their ratings for $Edwards Lifesciences (EW.US)$, with price targets ranging from $70 to $90.
J.P. Morgan analyst Robbie Marcus maintains with a hold rating.
BofA Securities analyst Travis Steed maintains with a hold rating, and maintains the target price at $75.
Citi analyst Joanne Wuensch maintains with a buy rating, and adjusts the target price from $77 to $81.
Barclays analyst Matt Miksic maintains with a buy rating, and maintains the target price at $85.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and maintains the target price at $80.
Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:
Edwards Lifesciences delivered a robust performance, surpassing sales and earnings expectations. The outlook for Q4 and the strategic vision set for 2025 are likely to sustain the stock's upward trajectory.
Following the Q3 report, there is a belief that it will require several more quarters for Edwards Lifesciences to demonstrate to investors that it has established a baseline for the performance of its TAVR franchise.
Expectations were modest prior to the release of the third-quarter results, and the subsequent discussion for the fourth quarter and fiscal year 2025 did not strongly indicate that risks were already priced in. Although the deceleration in fourth-quarter TAVR trends appears to be influenced by certain one-time factors, it remains challenging to definitively argue that TAVR growth will not continue to slow down in fiscal year 2025.
Here are the latest investment ratings and price targets for $Edwards Lifesciences (EW.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月29日，多家华尔街大行更新了$爱德华生命科学 (EW.US)$的评级，目标价介于70美元至90美元。
摩根大通分析师Robbie Marcus维持持有评级。
美银证券分析师Travis Steed维持持有评级，维持目标价75美元。
花旗分析师Joanne Wuensch维持买入评级，并将目标价从77美元上调至81美元。
巴克莱银行分析师Matt Miksic维持买入评级，维持目标价85美元。
富国集团分析师Larry Biegelsen维持买入评级，维持目标价80美元。
此外，综合报道，$爱德华生命科学 (EW.US)$近期主要分析师观点如下：
爱德华生命科学取得了强劲的业绩，超过了销售和收益预期。对于第四季度和2025年设定的战略愿景可能会维持股票的上升轨迹。
在第三季度报告之后，人们认为爱德华生命科学可能需要几个季度的时间向投资者展示其TAVR业务性能已经建立了基线。
在发布第三季度业绩之前，人们对预期并不是很高，随后讨论的第四季度和2025财年并没有明确表明风险已经反映在股价中。虽然第四季度TAVR趋势的减速似乎受到某些一次性因素的影响，但要明确地认为TAVR增长在2025财年不会继续放缓仍然具有挑战性。
以下为今日10位分析师对$爱德华生命科学 (EW.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
